Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Three-year Safety of Radium-223 in Patients with mCRPC and Symptomatic Bone Metastases
jul 2017 | Uro-oncologie